ArticleMovement disorders : official journal of the Movement Disorder Society2019
Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
Article in Movement disorders : official journal of the Movement Disorder Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 3 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis.Scientific reports · 2024Pooled it
- Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Rare Variants May Influence Disease Risk and Clinical Features in Sporadic Late-Onset Chinese Parkinson's Disease Patients.International journal of molecular sciences · 2026Article
- Understanding the genetic imperfections of Lewy body dementia.Molecular neurodegeneration · 2026Review
- Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.NPJ Parkinson's disease · 2026Article
- Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease.Journal of clinical laboratory analysis · 2026Article
- Investigating the Genetic Relationship Between Vitamin B12 Metabolism and Parkinson Disease.Neurology. Genetics · 2026Article
- Imaging and genome-supported association of glymphatic system function and multiregional brain characteristics with Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Identification of circulatory neuro-related proteins in Parkinson's disease: an integrated genetic-proteomic-clinical study.EBioMedicine · 2026Article
- Association of Statin use with Parkinson's Disease Progression in a Prospective Cohort Study and Multi-omics Analyses.Journal of molecular neuroscience : MN · 2026Article
- Cerebral microbleeds aggravate severity of motor function, cognitive and emotional status in Parkinson's disease.Acta neurologica Belgica · 2026Article
- A whole-transcriptome analysis of differentially expressed genes, transcripts, and transcript usage in blood samples from Parkinson's disease patients.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- No evidence for genetic role of the tumor necrosis factor pathway in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Biological relationship between Parkinson's disease and gallstone disease.Neuroprotection (Chichester, England) · 2025Review
- Elucidate biomarkers and the molecular pathways associated with genetic variants that contribute to the etiology of Parkinson's disease.Acta neurologica Belgica · 2025Article
- The APOE ε4 allele affects the survival of patients with Parkinson's disease independent of dementia.Journal of translational medicine · 2025Article
- No Evidence for Genetic Role of the Tumor Necrosis Factor Pathway in Parkinson's Disease.medRxiv : the preprint server for health sciences · 2025Article
- Genome-Wide Association Study of Glucocerebrosidase Activity Modifiers.Molecular neurobiology · 2025Article
- A Mendelian randomization study on association of alpha-synuclein and GPNMB with Parkinson's disease risk and progression.Molecular neurobiology · 2025Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 20 institutions in 7 countries.
Funding
Abstract
backgroundSeveral reports have identified different patterns of Parkinson's disease progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall contribution of genetic factors to the severity and progression of Parkinson's disease, however, has not been well studied.
objectivesTo test the association between genetic variants and the clinical features of Parkinson's disease on a genomewide scale.
methodsWe accumulated individual data from 12 longitudinal cohorts in a total of 4093 patients with 22,307 observations for a median of 3.81 years. Genomewide associations were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of interest, including 90 recently identified disease-risk variants, were also investigated post hoc for candidate associations with these phenotypes.
resultsTwo variants were genomewide significant. Rs382940(T>A), within the intron of SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (hazard ratio 2.04 [1.58-2.62]; P value = 3.46E-8). Rs61863020(G>A), an intergenic variant and expression quantitative trait loci for α-2A adrenergic receptor, was associated with a lower prevalence of insomnia at baseline (odds ratio 0.63 [0.52-0.75]; P value = 4.74E-8). In the targeted analysis, we found 9 associations between known Parkinson's risk variants and more severe motor/cognitive symptoms. Also, we replicated previous reports of GBA coding variants (rs2230288: p.E365K; rs75548401: p.T408M) being associated with greater motor and cognitive decline over time, and an APOE E4 tagging variant (rs429358) being associated with greater cognitive deficits in patients.
conclusionsWe identified novel genetic factors associated with heterogeneity of Parkinson's disease. The results can be used for validation or hypothesis tests regarding Parkinson's disease. © 2019 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.